Nuevas terapias en osteoporosis

Unnanuntana, 2010, The assessment of fracture risk, J Bone Joint Surg Am, 92, 743, 10.2106/JBJS.I.00919 Bouxsein, 2005, Determinants of skeletal fragility, Best Pract Res Clin Rheumatol, 19, 897e911, 10.1016/j.berh.2005.07.004 Manolagas, 2000, Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis, Endocr Rev, 21, 115e37 Recker, 2004, Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients, J Bone Min Res., 19, 1628, 10.1359/JBMR.040710 Segovia-Silvestre, 2009, Advances in osteoclast biology resulting from the study of osteopetrotic mutations, Hum Genet., 124, 561e77, 10.1007/s00439-008-0583-8 Ng, 2014, New therapeutics for osteoporosis, Curr Opin Pharmacol., 16C, 58, 10.1016/j.coph.2014.03.004 Cairoli, 2015, Perspectives on osteoporosis therapies, J Endocrinol Invest., 10.1007/s40618-014-0236-9 Capozzi, 2014, The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab, Gynecol Endocrinol., 30, 403, 10.3109/09513590.2014.892067 Diab, 2014, Denosumab in osteoporosis, Expert Opin Drug Saf., 13, 247, 10.1517/14740338.2014.860133 Sidlauskas, 2014, Osteoporosis in men: epidemiology and treatment with denosumab, Clin Interv Aging., 8, 593 Baron, 2011, Denosumab and bisphosphonates. Different mechanisms of action and effects, Bone., 48, 677, 10.1016/j.bone.2010.11.020 Miyazaki, 2014, A review of denosumab for the treatment of osteoporosis, Patient Prefer Adherence., 8, 463, 10.2147/PPA.S46192 Sims, 2014, Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib, Curr Osteoporos Rep., 12, 98, 10.1007/s11914-014-0196-1 Silva, 2012, Denosumab: recent update in postmenopausal osteoporosis, Acta Reumatol Port., 37, 302 Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, 756, 10.1056/NEJMoa0809493 Bone, 2013, The effect of three or six years of denosumabm exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension, J Clin Endocrinol Metab., 98, 4483, 10.1210/jc.2013-1597 Tsai, 2013, Teriparatide and denosumab, alone or combined, in women with posmenopausal osteoporosis: the DATA study randomised trial, Lancet., 382, 50, 10.1016/S0140-6736(13)60856-9 Leder, 2014, Two years of Denosumab and teriparatide administration in posmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial, J Clin Endocrinol Metab., 99, 1694, 10.1210/jc.2013-4440 Drooger, 2013, Denosumab in breast cancer treatment, Eur J Pharmacol., 717, 12, 10.1016/j.ejphar.2013.03.034 Smith, 2009, Denosumab in men receiving androgen-deprivation therapy for prostate cancer, N Engl J Med., 361, 745, 10.1056/NEJMoa0809003 Bone, 2012, Future directions in osteoporosis therapeutics, Endocrinol Metab Clin North Am., 41, 655, 10.1016/j.ecl.2012.05.003 Wensel, 2011, Effects of denosumab on bone mineral density and bone turnover in posmenopausal women, Pharmacotherapy., 31, 510, 10.1592/phco.31.5.510 Jamal, 2011, Effects of denosumab on fracture and bone mineral density by level of kidney function, J Bone Miner Res., 26, 1829, 10.1002/jbmr.403 Diz, 2012, Denosumab-related osteonecrosis of the jaw, J Am Dent Assoc., 143, 981, 10.14219/jada.archive.2012.0323 Neuprez, 2014, Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab, Osteoporos Int., 25, 393, 10.1007/s00198-013-2437-z Schipper, 2015, Treatment of osteoporosis in renal insufficiency, Clin Rheumatol., 34, 1341, 10.1007/s10067-015-2883-4 Ng, 2012, Potential role of odanacatib in the treatment of osteoporosis, Clin Interv Aging., 7, 235, 10.2147/CIA.S26729 Zerbini, 2013, Odanacatib in posmenopausal women with low bone mineral density: a review of current clinical evidence, Ther Adv Musculoskelet Dis., 5, 199, 10.1177/1759720X13490860 Schwarz, 2014, Status of drug development for the prevention and treatment of osteoporosis, Expert Opin Drug Discov., 9, 245, 10.1517/17460441.2014.884067 Costa, 2011, Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis, Nat Rev Rheumatol., 7, 447, 10.1038/nrrheum.2011.77 Duong le, 2012, Therapeutic inhibition of cathepsin K - reducing bone resorption while maintaining bone formation, Bonekey Rep., 1, 67, 10.1038/bonekey.2012.67 Eastell, 2011, Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study, J Bone Miner Res., 26, 1303, 10.1002/jbmr.341 Eastell, 2014, Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study, J Bone Miner Res., 29, 458, 10.1002/jbmr.2047 Bone, 2015, Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial, Osteoporos Int., 26, 699, 10.1007/s00198-014-2944-6 Appelman-Dijkstra, 2014, Novel approaches to the treatment of osteoporosis, Best Pract Res Clin Endocrinol Metab., 28, 843, 10.1016/j.beem.2014.07.003 Bromme, 2009, Cathepsin K inhibitors for osteoporosis and potential off-target effects, Expert Opin Investig Drugs, 18, 585, 10.1517/13543780902832661 Isabel, 2008, The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K, Bioorg Med Chem Lett, 18, 923, 10.1016/j.bmcl.2007.12.047 Stoch, 2013, Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers, Br J Clin Pharmacol., 75, 1240, 10.1111/j.1365-2125.2012.04471.x Anderson, 2014, Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women, J Clin Endocrinol Metab., 99, 552, 10.1210/jc.2013-1688 Marcantonio, 2014, Prednisone has no effect on the pharmacokinetics of CYP3A4 metabolized drugs - midazolam and odanacatib, J Clin Pharmacol., 54, 1280, 10.1002/jcph.338 Stoch, 2013, Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin, J Popul Ther Clin Pharmacol., 20, e312 Stoch, 2013, Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration, Int J Clin Pharmacol Ther., 51, 688, 10.5414/CP201864 Stoch, 2008, Cathepsin K inhibitors: a novel target for osteoporosis therapy, Clin Pharmacol Ther, 83, 172, 10.1038/sj.clpt.6100450 Chappard, 2010, The cathepsin K inhibitor AAE581 induces morphological changes in osteoclasts of treated patients, Microsc Res Tech., 73, 726 Rünger, 2012, Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib, J Am Acad Dermatol., 66, e89e96 Marzia, 2000, Decreased c-Src expression enhances osteoblast differentiation and bone formation, J Cell Biol., 151, 311, 10.1083/jcb.151.2.311 Horne, 2005, The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function, Immunol Rev., 208, 106, 10.1111/j.0105-2896.2005.00335.x Hannon, 2010, Effects of the src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial, J Bone Miner Res., 25, 463, 10.1359/jbmr.090830 Renouf, 2012, A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer, Invest New Drugs., 30, 779, 10.1007/s10637-010-9611-3 Musumeci, 2012, An update on dual Src/Abl inhibitors, Future Med Chem., 4, 799, 10.4155/fmc.12.29 Henriksen, 2004, Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2, Bone., 34, 140, 10.1016/j.bone.2003.09.009 Henriksen, 2007, Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women, Bone., 40, 723, 10.1016/j.bone.2006.09.025 Henriksen, 2009, Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD, Bone., 45, 833, 10.1016/j.bone.2009.07.008 Canalis, 2010, Update in new anabolic therapies for osteoporosis, J Clin Endocrinol Metab., 95, 1496, 10.1210/jc.2009-2677 Lippuner, 2012, The future of osteoporosis treatment–a research Update, Swiss Med Wkly., 142, w13624 Heath, 2009, Inhibiting dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma, J Bone Miner Res., 24, 425, 10.1359/jbmr.081104 Zhou, 2013, Dickkopf- 1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention, Blood Rev., 27, 261, 10.1016/j.blre.2013.08.002 Watts, 2014, Advances in target-specific therapy for osteoporosis, J Clin Endocrinol Metab., 99, 1149, 10.1210/jc.2014-1065 Weivoda, 2014, Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions, Curr Osteoporos Rep., 12, 107, 10.1007/s11914-014-0188-1 Lewiecki, 2011, Sclerostin monoclonal antibody therapy with AMG 785: a potential treatment for osteoporosis, Expert Opin Biol Ther., 11, 117, 10.1517/14712598.2011.540565 Padhi, 2011, Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody, J Bone Miner Res., 26, 19, 10.1002/jbmr.173 Padhi, 2014, Multiple doses of sclerostin antibody romosozumab in healthy men and posmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study, J Clin Pharmacol., 54, 168, 10.1002/jcph.239 McClung, 2014, Romosozumab in postmenopausal women with low bone mineral density, N Engl J Med., 370, 412, 10.1056/NEJMoa1305224 Becker, 2014, Sclerostin inhibition for osteoporosis–a new approach, N Engl J. Med., 370, 476, 10.1056/NEJMe1315500 ClinicalTrials.gov [homepage on the Internet]. Romosozumab. Clinical Trials.gov A service of the US National Institutes of Health.[citado 11 Feb 2015]. Disponible en: http://clinicaltrials.gov/ct2/results?term=romosozumab&Search=Search. McColm, 2014, Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibibody against sclerostin, in healthy postmenopausal women, J Bone Miner Res., 29, 935, 10.1002/jbmr.2092 Recker, 2015, A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density, J Bone Miner Res., 30, 216, 10.1002/jbmr.2351 Stolina, 2014, Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats, Bone., 67, 305, 10.1016/j.bone.2014.07.031 Cipriani, 2012, Safety of osteoanabolic therapy: A decade of experience, J Bone Miner Res., 27, 2419, 10.1002/jbmr.1800